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a  b  s  t  r  a  c  t
The  commitment  to and  execution  of  differentiation  programmes  involves  a signiﬁcant  change  in gene
expression  in  the  precursor  cell  to facilitate  development  of  the  mature  cell  type. In addition  to being  reg-
ulated  by lineage-determining  and  auxiliary  transcription  factors  that drive  these  changes,  the  structural
status of  the  chromatin  has  a considerable  impact  on  the transcriptional  competence  of differentiation-
speciﬁc  genes,  which  is clearly  demonstrated  by the large  number  of cofactors  and  the  extraordinary
complex  mechanisms  by which  these  genes  become  activated.  The  terminal  differentiation  of  myoblasts
to  myotubes  and  mature  skeletal  muscle  is  an excellent  system  to illustrate  these  points.  The  MyoD  family
of  closely  related,  lineage-determining  transcription  factors  directs,  largely  through  targeting  to  chro-
matin, a cascade  of  cooperating  transcription  factors  and enzymes  that  incorporate  or remove  variant
histones,  post-translationally  modify  histones,  and  alter  nucleosome  structure  and positioning  via  energy
released  by ATP  hydrolysis.  The  coordinated  action  of these  transcription  factors  and  enzymes  prevents
expression  of  differentiation-speciﬁc  genes  in myoblasts  and  facilitates  the transition  of  these  genes  from
transcriptionally  repressed  to activated  during  the  differentiation  process.  Regulation  is achieved  in both
a  temporal  as well  as  spatial  manner,  as at least  some  of  these  factors  and  enzymes  affect  local  chromatin
structure  at  myogenic  gene  regulatory  sequences  as well  as  higher-order  genome  organization.  Here we
discuss the  transition  of genes  that  promote  myoblast  differentiation  from  the silenced  to the  activated
state  with  an  emphasis  on the  changes  that  occur  to individual  histones  and  the  chromatin  structure
present  at these  loci.
©  2017  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The discovery of MyoD as a factor that could reprogram cells
of other lineages into skeletal muscle-like cells [1] established
the concept of lineage-determining transcription factors and made
skeletal muscle differentiation a model system for understanding
basic tenets about cellular differentiation (see also the article by
Lassar in this issue). Subsequent work determined that lineage
determination for skeletal muscle is mediated by the family of
related basic helix-loop-helix transcription factors that includes
MyoD, Myf5, Mrf4, and myogenin [2]. Each recognizes a DNA
sequence called an E box (consensus: CANNTG) common to reg-
ulatory sequences of genes expressed during skeletal muscle
differentiation [3], but, interestingly, these factors are dependent
on cooperating transcription factors. Speciﬁcally, the members of
the MyoD family interact with members of the ubiquitous E-protein
family to form functional heterodimers [4] and with members of
the Mef2 family of transcription factors to synergistically activate
myogenic genes ([5]; see also the article by Hughes and Taylor in
this issue). Additional transcription factors promote expression of
myogenic genes [6], leading to numerous combinations of factors
that cooperate with MyoD family member proteins to drive skeletal
muscle formation.
The most remarkable feature of MyoD and its paralogues is
the ability to drive new gene expression programmes that are
required to develop the skeletal muscle cell phenotype. Such activ-
ity necessarily involves activating silent genes, which of course are
incorporated into cellular chromatin. Thus differentiation-speciﬁc
gene expression requires mechanisms to alleviate the effects of
repressive chromatin and additional mechanisms to promote the
activity of transcription factors and RNA polymerase II in a chro-
matin environment conducive to active gene expression.
The basic unit of chromatin is the nucleosome, which is com-
posed of 147 bp of DNA wound ∼1.8 turns around a globular
octamer of histone proteins containing two copies of each of the
four core histones: H2A, H2B, H3 and H4 [7]. Nucleosomes are
arranged linearly on the DNA as arrays, and fold into higher order
structures in conjunction with the linker histone H1, which is
present stoichiometrically with nucleosomes. Detailed structural
and biophysical understanding of nucleosome array structures con-
sisting of a dozen or more nucleosomes is still somewhat limited
[8]. Ultimately, however, these arrays form interphase chromatin
containing loops and other higher-order structures that deﬁne the
physical state of the genome. When genes are activated, chro-
matin structure at the locus is altered and generally becomes
less compacted, originally documented by relative increases in
accessibility to nuclease digestion [9,10]. Consistent with such ﬁnd-
ings, genes associated with skeletal muscle differentiation were
shown to acquire nuclease sensitivity upon differentiation [11].
Subsequent genome-wide probing documented skeletal muscle
differentiation-dependent changes in nuclease sensitivity that led
to deﬁned changes in nucleosome positioning [12,13]. How the
chromatin structural changes represented by these increases in
nuclease sensitivity are achieved at differentiation-speciﬁc genes is
the focus of this review. We  will address the changes in chromatin
composition and structure caused by enzymes that incorporate
variant histones, that modify histones post-translationally, that
alter chromatin structure via ATP hydrolysis, and that contribute
to higher order chromatin structure. We  will cover these topics
in a manner following temporal events at these loci, ﬁrst describ-
ing the repressed state, then moving toward changes immediately
preceding or concurrent with differentiation signaling, and then
progressing to activated chromatin at transcriptionally active myo-
genic genes. Some chromatin modiﬁcations and structural changes
are functionally understood; others are not but can be consistently
correlated with transcriptionally activated, poised, or inactive chro-
matin and/or with other regions of the genome. The review will
concentrate on terminal differentiation of myoblasts; activation of
gene expression in quiescent satellite cells, the adult stem cells
responsible for post-natal growth and recovery from injury, is a
topic of great interest that has been reviewed extensively in recent
years [14–18] and will not be covered in depth here.
2. The chromatin state of repressed myogenic loci
2.1. Histone modiﬁers and modiﬁcations prior to myoblast
differentiation
Silencing of myogenic genes associated with terminal differ-
entiation in proliferating precursor cells is mediated through a
combination of chromatin modifying enzymes that generate well-
known histone marks associated with gene repression. Among
these are preclusion of histone acetylation and deposition of lysine
methylation at H3K9 and H3K27.
Type I and type II histone deacetylases (HDACs), which are
distinguished from each other based on relative sequence homol-
ogy [19], maintain hypoacetylated chromatin at the promoters of
myogenic genes and also prevent acetylation of MyoD and other
non-histone components of the transcriptional machinery. The
type I HDACs, HDAC1 and HDAC2, associate with MyoD [20,21] and
are recruited to myogenic promoters by MyoD and as well as by
the ubiquitous transcription factor YY1 [22,23]. More recent work
implicates the repressor Snail as an additional factor that recruits
type I HDACs as a mechanism to prevent MyoD binding [24].
Type II HDACs typically associate with Mef2 proteins and repress
Mef2-based transcriptional activity [25], at least in part through
association with a corepressor complex called NCOR/SMART [26].
Members of a third type of HDAC class are related to the NAD+
dependent Sir2 deacetylase protein of yeast. These HDACs asso-
ciate with MyoD and the acetyltransferase PCAF to prevent PCAF
activity and MyoD acetylation and may  act as a redox sensor to
regulate chromatin structure in response to changing physiological
conditions [27].
The Polycomb group (PcG) proteins were deﬁned genetically
in Drosophila as repressors of developmentally regulated tran-
scription [28,29]. Subsequent characterization revealed that PcG
proteins form two distinct complexes, PRC1 and PRC2 [30,31], the
latter of which contains the lysine methylase Ezh2, which catalyzes
trimethylation on H3K27 [32–35] Targeting of PRC2 to myogenic
genes occurs through YY1 [22], thereby giving YY1 a central role in
two gene silencing mechanisms. A distinct repression mechanism,
catalyzed by the Suv39H1 methyltransferase, results in methyla-
tion of H3K9 [36], providing a binding site for heterochromatin
protein 1 [37,38] which interacts with MyoD and represses its
transcriptional activity [23,39]. Another methyltransferase, G9a,
dimethylates H3K9 and MyoD [40] repressing the transcriptional
activity of the transcription factor as well as promoting a repres-
sive chromatin environment. However, knockout of G9a in mouse
skeletal muscle has no phenotype despite a global reduction in
dimethylated H3K9 [41], possibly suggesting redundant function
of another methyltransferase or a contributory but not essential
role. A schematic compilation of the enzymes implicated in these
post-translational modiﬁcations is presented in Fig. 1 (top).
2.2. Chromatin remodeling and histone variants prior to
myoblast differentiation
Variants of three of the four core histones (H2A, H2B, H3) exist
and play specialized roles in different biological processes. To date,
there is no evidence for a role for H2B variants in myogenesis [42].
Replacement of canonical histones with histone variants of H2A
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Fig. 1. Chromatin regulators of proliferating and differentiating myoblasts. (Top) In proliferating myoblasts, expression of differentiation-speciﬁc genes in the skeletal muscle
lineage is repressed. MyoD is associated with several transcription factors, including YY1, Pbx1, and Snail. Histone modifying enzymes, including the PRC2 complex, Suv39H1,
G9a  and Type I/II HDACs, establish repressive histone marks. Two  components of distinct ATP-dependent chromatin remodeling enzymes, Baf60c and Chd2, are also present.
(Bottom) During differentiation, muscle-speciﬁc genes are transcriptionally activated via chromatin remodeling by the SWI/SNF remodeling complex. Repressive histone
marks  are erased and active histone marks are established by the histone demethylases UTX and KDM4a, p300/CBP acetyltransferases, and the histone methyltransferases
MLL,  Prmt5 and Prmt4/Carm1. Variant histone, represented by the orange nucleosomes, are present in both conditions but are present at elevated levels in differentiating
cells.  See text for relevant citations.
and H3 contributes to the regulation of gene expression during
skeletal muscle differentiation. The histone H2A variant macroH2A
(mH2A) is characterized by the presence of a ∼25 kDa evolutionar-
ily conserved carboxyl-terminal domain called the macro domain,
which makes the protein nearly three times larger than its canoni-
cal counterpart. Evidence suggests the genome-wide distribution of
mH2A is similar in myoblasts and in differentiated myotubes and
is predominantly associated with regions of active transcription
[43]. Regions of co-localization of mH2A with trimethylated H3K27
in myoblasts was also reported, but knockdown of mH2A has no
effect on this modiﬁcation and no major effect on gene expression,
suggesting that it is not required or is redundant for repression
of gene expression in the undifferentiated state [43]. This ﬁnd-
ing is consistent with reports from other systems [44]. However,
mH2A is necessary for the recruitment of the homeodomain tran-
scription factor Pbx1 to some myogenic promoters and enhancers,
which then contributes to the recruitment of MyoD and expression
of differentiation-speciﬁc gene expression [43,45–47]. In addition,
mH2A promotes inclusion of an activating histone mark, acetylated
H3K27, at myogenic enhancers and promoters [48]. How mH2A is
deposited and its exact role in myoblast chromatin remain to be
determined.
H3.3 is a H3 variant that, unlike the canonical H3 isoforms, H3.1
and H3.2, is deposited in chromatin in a replication-independent
manner. Deposition is widespread throughout the genome; it
occurs at both active and inactive genes, and in other genomic
regions, including enhancers, telomeres, and retroviral elements.
Multiple H3.3 chaperones exist, including a SNF2 family enzyme
called ATRX, which deposits H3.3 into heterochromatin with a part-
ner protein called DAXX, a multi-functional protein that interacts
with H3.3/H4 dimers [49]. Though ATRX and DAXX can be local-
ized to heterochromatin in differentiating myoblasts [50], to date
no connection between ATRX and H3.3 deposition in proliferating
or differentiating myoblasts has been reported.
A general question about the association of H3.3 with actively
transcribing genes was whether or not this modiﬁcation was a
cause or consequence of transcription. Considerable insight was
gained from experiments probing transcriptional memory using
Xenopus somatic cell nuclear transfer. Nuclei expressing MyoD
were transferred into enucleated eggs and underwent up to 24
rounds of cell division prior to the acquisition of transcriptional
competence. MyoD expression was  observed when transcriptional
competence was  established, despite the large number of inter-
vening cell divisions. Overexpression of either wildtype or mutant
H3.3 increased H3.3 deposition at the MyoD as well as at the Myf5
locus, but the mutant H3.3 could not support transfer (memory) of
the expressed state. In other words, the presence of the wildtype
H3.3 was required for the recipient embryo to be able to express
MyoD. Because of the extended period of cell division in the absence
of transcriptional competence, these experiments strongly suggest
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that H3.3 deposition is a precursor for subsequent transcription
[51].
Subsequent work directly addressed this issue at
differentiation-speciﬁc genes in proliferating and differentiating
myoblasts [52]. Chd2, an ATP-dependent chromatin remodeling
enzyme from the SNF2 family, interacts with MyoD and binds to
differentiation-speciﬁc genes in both proliferating and differen-
tiating myoblasts (Fig. 1 –top panel). Chd2 knockdown inhibits
myogenic gene expression and differentiation, and remarkably,
prevents incorporation of H3.3 into differentiation-speciﬁc genes
prior to gene activation, thereby demonstrating that H3.3 incorpo-
ration precedes gene activation during myogenic differentiation.
Chd2 interacts with H3.3, suggesting that the remodeling enzyme
may  act as an H3.3 chaperone [52]. Conversely, knockdown of H3.3
or ectopic expression of H3.1, one of the canonical H3 proteins, in
myoblasts increases incorporation of H3.1 at the expense of H3.3
incorporation, increases trimethylation of H3K27 while decreas-
ing methylation of H3K4, and inhibits myoblast differentiation,
revealing how the balance of H3 isoforms in myoblasts regulates
differentiation potential [53].
In mammals, H3.3 differs from the canonical H3.1 and H3.2 his-
tones by only ﬁve (Ser31, Ala87, Ile89, Gly90, Ser96) or four amino
acids (Ser31, Ala87, Ile89, Gly90), respectively [54]. Amino acids
87–90 determine variations in deposition timing and localization
that correspond to the interactions of preferred chaperones for the
H3.1/H3.2 and H3.3 variants [55–57]. Recent work showed that
Ser31 was necessary for H3.3 to promote myogenic gene expres-
sion [53]. Additional details describing the mechanism by which
this seemingly very speciﬁc requirement results in such signiﬁcant
changes in myoblast chromatin structure await further study. It
is possible that there are reader proteins that speciﬁcally bind to
H3.3 or that recognize known histone modiﬁcations in the context
of H3.3. One example is the zinc ﬁnger MYND-domain containing
protein 11 (ZMYND11), which is a reader protein for H3.3-speciﬁc
trimethylation of K36 [58]. In other systems, ZMYND11 regulates
transcriptional elongation of RNA Polymerase II via its recogni-
tion of trimethylated H3K36 on H3.3. There is only one report
of H3K36 trimethylation in myoblasts, but this work did not dis-
tinguish between H3 isoforms [59]. Whether this or any other
histone modiﬁcation relates to the functionality of H3.3 remains
to be determined. Fig. 2 (top) is a schematic diagram showing
post-translational modiﬁcations and variant histones present at
myogenic loci prior to differentiation.
3. The chromatin state at active myogenic loci
3.1. Changes in histone modiﬁers and modiﬁcations upon
myoblast differentiation
The transition between repression and activation of
differentiation-speciﬁc genes requires both the removal of repres-
sive marks and the deposition of histone marks associated with
gene activation. At the earliest stages of myoblast differentiation,
promoters controlling the expression of differentiation-speciﬁc
genes become hyperacetylated in a MyoD- or Myf5-dependent
manner [46,60,61]. This is accomplished by downregulation of
Snail, HDACs and Ezh2 levels and the alleviation of repression
of acetyltransferase activity [22,24,62,63]. In addition, repres-
sion mediated through trimethylation of H3K27 is relieved via
the activity of the lysine demethylase UTX. Removal of H3K27
methyl marks facilitates targeting of the Ash2L complex via the
Mef2D and Six1 transcription factors [6,64]. The Ash2L complex
trimethylates H3K4 via enzymatic subunits of the MLL  family [65],
thereby assisting in a chromatin transition from repressive H3K27
methylation to permissive H3K4 trimethylation. Interestingly,
demethylation of H3K27 needs to precede trimethylation of H3K4
because methylation of H3K27 precludes binding of the Ash2L
methyltransferase complex [66]. The histone acetyltransferases
p300/CBP also antagonize H3K27 methylation activities by acety-
lating this amino acid [67]. Removal of H3K9 methylation is not
as well understood. One report indicates that a novel isoform of
the KDM4A demethylase that is upregulated upon differentia-
tion signaling mediates H3K9 demethylation and is required for
myogenic differentiation [68]. KDM4A also demethylates MyoD
protein, which results in an increase in its stability [69]. Additional
investigation is warranted. In particular, information on the tem-
poral relationships and inter-dependencies, if any, between the
enzymes that relieve hypoacetylation and that remove H3K27 and
H3K9 trimethylation may  reveal mechanistic details that explain
the integration of each of these enzymatic reactions.
Additional coactivators involved in modifying chromatin struc-
ture in differentiating myoblasts include members of the arginine
methyltransferase (PRMT) family. Arginine methylation yields
monomethylation or either symmetric or asymmetric dimethyla-
tion [70,71]. Prmt5 is a symmetric arginine dimethylase of H3R8
and H4R3 that was  originally characterized as a transcriptional
repressor of cell proliferation [72–74]. There are reports of Prmt5
functioning as a co-repressor in some differentiation systems
[75–77], but Prmt5 binding and symmetric dimethylation of H3R8
are induced at myogenic promoters after differentiation signaling,
correlating with the onset of differentiation-speciﬁc gene expres-
sion [78,79]. Though Prmt5 binds to myogenin and several other
gene promoters that are expressed later during myogenic differ-
entiation, it is only required for myogenin expression, as ectopic
expression of myogenin in Prmt5 knockdown cells rescues the
expression of these late genes [78]. Remarkably, a different PRMT,
Prmt4, also called Carm1, that asymmetrically dimethylates H3R17
and H3R26 [80], is not required for myogenin expression but
binds to late gene promoters, locally dimethylates H3R17, acts as
a cofactor for the Mef2 transcription factor [81] and is required
for expression of these genes [78]. Subsequent efforts determined
that microRNAs induced during myogenic differentiation show the
same differential requirement; Prmt5 is required for myogenin
expression, which is required, along with Carm1, for microRNA
expression [82]. A review on myogenic miRNAs by Munsterberg
can be found elsewhere in this issue. Thus, there is a temporal rela-
tionship between the activities of different PRMTs in the activation
of differentiation-speciﬁc genes during myoblast differentiation.
The roles of PRMTs in myogenesis appear to be more complex
than just contributing to differentiation-speciﬁc gene expression.
In vivo analysis of Prmt5 and Carm1 function in zebraﬁsh also
demonstrated a differential but combinatorial role for both of
these PRMTs in overall skeletal muscle development [83]. In par-
ticular, it was reported that both Prmt5 and Carm1 contribute to
myogenin expression, whereas the two enzymes differ in require-
ment for slow vs fast muscle ﬁber formation [83]. Later work
used genetic depletion or depletion via electroporation of shRNA
in mouse skeletal muscle to further probe function. Depletion
of the Prmt5-associated factor Copr5 hinders regeneration of
injured skeletal muscle [84], while genetic knockout of Prmt5
severely inhibits skeletal muscle regeneration after injury [85].
Interestingly, while genetic knockout studies conﬁrm a role for
Prmt5 in post-natal differentiation, they also show that Prmt5
is not required for embryonic skeletal muscle differentiation
[85]. However, molecular evidence demonstrates both Prmt5 and
dimethylated H3R8 on the myogenin promoter in isolated somites
dissected from E8.25–E9.5 embryos [86], suggesting that Prmt5
and H3R8 dimethylation are likely contributing to embryonic gene
activation even if not absolutely required.
Many differentiation-speciﬁc genes also have enhancer
sequences contributing to their expression. Genome-wide pro-
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Fig. 2. Histone modiﬁcations and histone variants involved in chromatin structure at differentiation-speciﬁc genes prior to and during myogenesis. In proliferating myoblasts
(top  panel), post-translational modiﬁcations on the histone N-terminal tails that are present are shown. Nucleosomes contain the histone variants H3.3, mH2A and H2A.Z.
The  presence of these variants signiﬁes commitment but not expression of differentiation-speciﬁc genes. H3.3 comprises 20–40% of the total H3 pool, while mH2A and H2A.Z
each  comprise about 1% of the total H2A pool [49,148]. In differentiated cells (bottom panel), post-translational histone modiﬁcations associated with active transcription
are  shown. The histone variants H3.3 and H2A.Z are more enriched than in proliferating cells, which is signiﬁed by the red arrows. The H3.3 variant can harbor different
post-translational modiﬁcations during differentiation. See text for relevant citations.
ﬁling also implicates MyoD as an organizer of active enhancers.
Incorporation of monomethylated H3K4 via the Set7 methyl-
transferase and acetylated H3K27 by p300, along with binding of
RNA polymerase II and the transcription factors Runx1 and c-jun,
among others, mark these enhancers [87,88]. Myogenic enhancers
are also a source of non-coding enhancer RNAs, short RNAs that
promote MyoD-mediated gene activation in a manner that seems
to involve increasing chromatin accessibility through an undeﬁned
mechanism [89,90].
In contrast to MyoD binding, which can be identiﬁed at many
myogenic genes prior to and at the onset of differentiation signaling
[60], the transition from repressed to active chromatin generally
correlates with the onset of gene expression. This is facilitated,
at least in part, by the continued association of MyoD with HDAC
proteins at promoters that are not expressed until later in differ-
entiation, even though other differentiation-speciﬁc genes are no
longer bound by HDACs and co-repressors and are being actively
transcribed [86,91,92]. The functionality of this interaction was
revealed by experiments demonstrating that ectopic expression of
myogenin and Mef2D prevented HDAC association with promoters
expressed at later times and resulted in premature expression of
these genes [91]. Thus the chromatin state of different genes can
be different, with actively transcribing genes showing MyoD and
coactivators bound, simultaneously existing with MyoD and HDAC
bound, transcriptionally repressed genes. Triggers that stimulate
the conversion of late expressed genes from an inactive conforma-
tion marked by repressive histone marks to the active state remain
to be determined. Fig. 1 (bottom) shows a schematic diagram
indicating the presence of enzymes implicating in transitioning
chromatin at differentiation-speciﬁc genes from the repressed to
the active state.
3.2. Chromatin remodeling and histone variants upon myoblast
differentiation
Genetic ablation of MRF  genes in the mouse demonstrated that
MyoD and Myf5 are determinants of the skeletal muscle lineage
while myogenin drives terminal differentiation. The Mrf4 factor
likely contributes to both processes [2]. An initial investigation
into the mechanisms of chromatin alteration at differentiation-
speciﬁc genes during myogenesis compared the activities of MyoD
and myogenin in inducing nuclease sensitivity, a proxy for local
chromatin structural changes, at myogenic regulatory sequences.
MyoD proved efﬁcient at inducing changes in chromatin accessi-
bility whereas myogenin was  not [11]. Structure-function analysis
identiﬁed regions of the MyoD protein conserved with Myf5 that
were distinct from the known activation and DNA binding domains
and that were necessary for mediating chromatin accessibility, and
it was  suggested that these domains mediated interaction with
factors capable of directly altering chromatin structure [11].
The mammalian SWI/SNF chromatin remodeling enzyme
complexes were identiﬁed and shown biochemically to alter nucle-
osome structure in an ATP-dependent manner in vitro [93,94]. The
ATPases acting as the catalytic components of these complexes,
called Brahma (Brm) and Brg1 (Brahma related gene 1) [95,96]
belong to the SNF2 family of DNA-dependent ATPases that had
been implicated via yeast genetic approaches as regulators of chro-
matin structure [97]. Expression of ATPase-deﬁcient alleles of these
enzymes resulted in a dominant negative effect, as enzyme com-
plexes formed around the nonfunctional ATPases and interfered
with gene expression and cellular function [95,96,98]. Using this
approach, reprogramming to the skeletal muscle lineage by MyoD
and other MRF  family members was shown to be dependent on the
SWI/SNF ATPases because chromatin remodeling at myogenic loci
could not occur [99,100]. The requirement for energy-dependent
chromatin alterations at differentiation-speciﬁc genes is consistent
with a coordinated, genome-wide transition of the cohort of genes
needed to promote a new cellular phenotype from a repressed,
transcriptionally silent state to a transcriptionally competent con-
ﬁguration.
Initial genome-wide assessment of myogenic gene expression
suggested that the requirement for SWI/SNF enzymes varied from
modest to completely dependent at different loci and that chro-
matin remodeling followed histone acetylation [46]. The presence
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of bromodomains, which promote binding to acetylated chro-
matin [101,102] in at least three subunits of SWI/SNF complexes,
including the Brm and Brg1 ATPase subunits, suggests a mech-
anism that enables association of the SWI/SNF enzymes with
chromatin. While likely not essential for every SWI/SNF-mediated
cellular function [103–106], a bromodomain inhibitor speciﬁc for
the three SWI/SNF bromodomain proteins nevertheless negatively
impacts myoblast differentiation [107], suggesting a contributing
role for bromodomain-mediated chromatin interactions. Similarly,
knockdown of either the Prmt5 or Carm1 methyltransferases pre-
cludes SWI/SNF enzyme binding and function [78,79], indicating
that dimethylation of histone arginines or other PRMT substrates
and/or the interaction of a reader of dimethylated histone arginines
is a necessary prerequisite for ATP-dependent remodeling of
differentiation-speciﬁc loci. No formal relationship between the
MLL  enzymes mediating H3K4 methylation and SWI/SNF enzyme
function during myogenic gene activation exists.
The different SWI/SNF enzyme ATPases appear to play distinct
roles in differentiation. Brg1 is essential for driving proliferating
myoblasts into differentiation [108] and via ChIP has been impli-
cated as being present at myogenic gene regulatory sequences
in developing somites and limb buds [86,92]. Mechanistically,
the alteration of chromatin structure by SWI/SNF enzymes at
differentiation-speciﬁc genes results in stable interaction of MyoD
and Mef2 transcription factors, and likely facilitates the binding of
additional transcription factors [46,92]. At some myogenic loci, the
interaction of Brg1 and MyoD are facilitated by the Pbx1 home-
odomain transcription factor [45–47], resulting in stabilization
of MyoD binding. More speciﬁc roles for the BRM ATPase have
recently been reported. BRM is required for cell cycle arrest prior
to differentiation and seems to play a role in the activation of
some differentiation-speciﬁc genes that are expressed late in the
differentiation process [109]. In general, understanding of the phys-
iological roles of the BRM ATPase has been hampered by a lack of
consistently available antibodies and concerns about the existing
knockout mouse model [110]. Distinguishing speciﬁc and coopera-
tive functions of the SWI/SNF ATPases remains a general challenge;
it is likely that the interplay between the two enzymes is complex
and highly relevant to understanding chromatin structural changes
during myogenesis.
The interaction of the SWI/SNF enzymes with myogenic genes
is also facilitated by regulated phosphorylation and dephospho-
rylation of speciﬁc subunits. Most, if not all SWI/SNF subunits
are heavily phosphorylated [111], and regulated phosphorylation
of the Brg1 and Brm ATPases is required for cell proliferation
[112]. The Baf60c subunit interacts with MyoD and with myo-
genic gene promoters prior to differentiation signaling. Baf60c is
phosphorylated by the p38/ mitogen activated protein (MAP)
kinase upon differentiation signaling, which permits the associ-
ation of the ATPase and other enzyme subunits and subsequent
chromatin remodeling of local chromatin structure [113,114].
SWI/SNF enzyme binding to chromatin and function is also reg-
ulated by the phosphorylation state of the Brg1 ATPase, which is
controlled by opposing, calcium-dependent enzymes. In prolifer-
ating myoblasts, Brg1 is phosphorylated by PKC1. Shortly after
the onset of differentiation, calcineurin dephosphorylates Brg1
at PKC1 dependent sites, permitting association with myogenic
regulatory sequences and chromatin remodeling function [115].
Surprisingly, both PKC1 and calcineurin can be localized to myo-
genic gene promoters in association with Brg1, but in a mutually
exclusive, temporally separable manner [115]. Recent evidence
shows additional regulation of Brg1-mediated chromatin remodel-
ing in proliferating myoblasts by casein kinase 2 [116]. Regulation
of chromatin remodeling by post-translational modiﬁcation of sub-
unit proteins indicates that simply targeting remodeling enzymes
via interactions with transcription factors is likely an insufﬁcient
mechanism to regulate chromatin remodeling activity. It also raises
the possibility of additional modes of regulation through other
post-translational modiﬁcations of the subunit proteins.
Other ATP-dependent remodeling enzymes exist and in dif-
ferent contexts work in cooperation or opposition to SWI/SNF
enzymes [117]. To date, enzymes from other SNF2 ATPase fami-
lies have been studied in more limited detail during the activation
of skeletal muscle differentiation. An ATPase called Chd4, which is
part of a remodeling enzyme called NuRD [118], causes inappro-
priate expression of cardiac muscle-speciﬁc genes when depleted
in mouse skeletal muscle [119], perhaps suggesting a repres-
sive role for the NuRD complex at cardiac and perhaps other
genes to prevent their induction during skeletal muscle differ-
entiation. SRCAP (SNF2-related CBP activator protein) is one of
two mammalian enzymes that modulates chromatin structure by
exchanging canonical H2A for the H2A.Z variant [120–122]. The
H2A.Z variant was  originally characterized in yeast as a positive
regulator of transcription using approaches combining genetics
with molecular analyses of chromatin structure and composi-
tion [123,124], but multiple later reports using global analyses
of histone incorporation and gene expression showed it can be
found at both active and repressed genes with apparent roles in
both activation and repression [125–130]. During myoblast dif-
ferentiation, the SRCAP subunit called p18Hamlet is upregulated
in a manner dependent on p38 kinase signaling. Though a basal
level of H2A.Z can be found in myogenic chromatin in prolifer-
ating myoblasts, both p18Hamlet binding and H2A.Z incorporation
are induced at myogenic promoters early after the onset of dif-
ferentiation, and knockdown of the p18Hamlet subunit inhibited
differentiation-speciﬁc gene expression and myoblast differenti-
ation [131]. It should be noted that a recent report indicates H2A.Z
is also present at the MyoD locus in myoblasts and that its ability to
be acetylated is critical for MyoD expression, thereby providing an
indirect mechanism for a role for deposition of H2A.Z in myoblasts
impacting differentiation [132]. Whether or not deposition of H2A.Z
at myogenic sequences prior to differentiation requires SRCAP,
p400, or a different cooperating enzyme is unknown.
Finally, though deposition of the H3.3 variant at differentiation-
speciﬁc genes was  shown to occur in proliferating myoblasts
in a manner dependent on the Chd2 ATP-dependent chromatin
remodeling enzyme, incorporation of H3.3 at the MyoD locus was
reported to happen as differentiation proceeded [133]. Deposition
was mediated by the histone chaperones Hira (histone cell cycle
regulator) and Asf1A (Anti-silencing function protein 1 homolog A).
Knockdown of Hira compromised MyoD expression, which blocked
activation of differentiation-speciﬁc genes, thereby preventing dif-
ferentiation [133]. Later work conﬁrmed that knockdown of Chd2
had no effect on H3.3 incorporation at the MyoD locus [52]. It is
unclear why the MyoD locus requires different H3.3 chaperones
and why the kinetics of H3.3 deposition are different from those
of differentiation-speciﬁc genes. The data reﬂect a further com-
plexity in orchestrating the activation of gene expression during
myoblast differentiation. Fig. 2 (bottom panel) schematically shows
post-translational modiﬁcations and variant histones present at
myogenic loci upon differentiation.
3.3. Changes in higher order chromatin organization during
myoblast differentiation
An increasingly apparent concept is that higher order chromatin
organization is dynamic and changes in response to myriad signal-
ing events [134]. Chromosome conformation capture methodology
has provided direct physical evidence for promoter-enhancer
looping changes that increase or decrease as a result of myo-
genic differentiation [135–138]. A recent low-resolution (400 kb)
genome-wide analysis of chromatin interactions in myoblasts
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pre- and post-differentiation showed overall similarity in genome
organization despite the change in differentiation state. The res-
olution achieved precluded identifying gene-speciﬁc interactions
but nevertheless showed that differentiation did induce some com-
partment switching, indicating interconversion of speciﬁc regions
of hetero- and euchromatin in myoblasts and myotubes [139].
Detailed mechanistic studies about myogenic higher order chro-
matin organization are limited. A candidate gene approach using
chromosome capture methods in cell lines and primary tissue
reported the trans-interaction of promoter sequences of different
genes expressed late in differentiation, despite being located on
different chromosomes. Interactions between the implicated loci
were conﬁrmed by FISH [91]. No interactions between these “late”
genes and an early gene, myogenin, or between these genes and cel-
lular housekeeping genes, were detected. These interactions occur
at the onset of differentiation prior to gene expression and are not
detected once gene expression was initiated, thereby correlating
with repression of the “late” genes at early times. Transcriptionally
active genes are concentrated on the genome into what are known
as RNA Polymerase II foci or “specialized transcription factories”
[140,141]. It appears the physical convergence of these myogenic
genes represents the converse situation: a concentration of genes
that are not expressed but are poised to be activated later in the
differentiation cascade. Formation of the interactions is dependent
on MyoD, and by implication, the HDAC associated with MyoD at
early times of differentiation, and on the Brg1 SWI/SNF ATPase
[91]. Brg1 was already known as a required element in organiz-
ing local higher-order chromatin structures at complex loci such as
-globin, -globin, Th2, and CIITA [142–145], and a recent genome-
wide assessment of intra- and inter-chromosomal interactions in
a different cell type suggests a global role for Brg1 in higher-order
chromatin organization [146]. Collectively, the data suggest that
chromatin remodeling by Brg1 and SWI/SNF enzymes very likely
is an essential component in the regulation of genome-wide chro-
matin structure both prior to and during myogenic differentiation.
A point of future research will be to determine how the chromatin
remodeling enzyme contributes to overall genome organization.
It is known to locally remodel nucleosome structure at regula-
tory sequences to facilitate factor binding and utilization of the
DNA for transcription as well as replication, recombination, and
repair. It is possible that this function is sufﬁcient to translate to
regulation of genome organization, but it may  be that there is a
separate chromatin remodeling function to support factors speciﬁ-
cally involved in regulating chromatin looping and compaction and
or factors involved in maintaining nuclear integrity. A speculative
model discussing this hypothesis has been published [147].
4. Conclusions
The number of possible changes to chromatin structure due to
the incorporation of different histone variants, the incorporation
of different histone modiﬁcations, and the function of chromatin
remodeling enzymes seems almost limitless. Many different cofac-
tors play a role in establishing a repressive chromatin state at
differentiation-speciﬁc genes in myoblasts, yet it is interesting that
some of the cofactors and transcription factors that are present
prior to gene expression are also central players in the transition
from a repressed to an activated chromatin conformation. By neces-
sity, the discussion here is oversimpliﬁed. Different studies cited
utilized different cell types and different approaches, with some
providing readout on a single gene, some presenting several candi-
date genes, and others providing genome-wide data. It is unlikely
that every factor and every modiﬁcation or variant is present at
every differentiation-speciﬁc gene that is activated during myo-
genesis; there are almost certainly subsets of genes that have
shared mechanisms, but there are likely to be signiﬁcant differ-
ences as well. Nevertheless, as illustrated in the schematic ﬁgures,
signiﬁcant progress has been made in identifying the major play-
ers and mechanisms that mediate both repressive and activated
chromatin at myogenic genes. Better understanding of temporal
regulation of these mechanisms will likely increase general under-
standing of the transition of chromatin states at myogenic genes.
Single cell analysis is one possible approach for accomplishing this
goal. Rapidly improving methodologies in this arena should make
possible integrated analyses of changes in the transcriptome and
epigenome during skeletal muscle differentiation and will likely
generate a more precise, genome- and population-wide picture of
differentiation-dependent alterations in chromatin structure dur-
ing myogenic differentiation.
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